

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/980,620	12/05/2001	Makoto Ozeki	1422-0507P	8140
2292	7590 11/05/2002	•		
BIRCH STEWART KOLASCH & BIRCH			EXAMINER	
PO BOX 747		SHEIKH, HUMERA N		
FALLS CHUI	RCH, VA 22040-0747		Ç1121141, 11	J. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.
			ART UNIT	PAPER NUMBER
			1615	
			DATE MAILED: 11/05/2002	5

Please find below and/or attached an Office communication concerning this application or proceeding.

· 35 ± ·					
		Application No.	Applicant(s)		
,	Office floring Comment	09/980,620	OZEKI ET AL.		
Office Action Summary		Examiner	Art Unit		
		Humera N. Sheikh	1615		
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status					
1) Responsive to communication(s) filed on <u>05 December 2001 (paper no.4)</u> .					
2a)☐ Thi	s action is <b>FINAL</b> . 2b)⊠ Thi	s action is non-final.			
	ce this application is in condition for allowa				
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. <b>Disposition of Claims</b>					
4)⊠ Claim(s) <u>1-5</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>1-5</u> is/are rejected.					
7)∏ Clai	m(s) is/are objected to.				
8) Claim(s) are subject to restriction and/or election requirement.					
Application Papers					
9) The specification is objected to by the Examiner.  10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.					
, —					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.					
12) The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a)⊠ All b) Some * c) None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s)					
2) Notice of D	teferences Cited (PTO-892) praftsperson's Patent Drawing Review (PTO-948) profitsperson's Patent Drawing Review (PTO-948) profitsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal (	y (PTO-413) Paper No(s) Patent Application (PTO-152)		

Application/Control Number: 09/980,620

Art Unit: 1615

**DETAILED ACTION** 

Status of the Application

Acknowledgement is made of the receipt of the IDS and the Preliminary

Amendment, both filed 12/05/01.

Claims 1-5 are pending. Claims 1-5 are rejected.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter, which the applicant regards as his invention.

Claim 5 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite

for failing to particularly point out and distinctly claim the subject matter which applicant

regards as the invention.

Claim 5 provides for the use of theanine for preparation of food or a medicament

for an individual having sleep disorders, but, since the claim does not set forth any steps

involved in the method/process, it is unclear what method/process applicant is intending

to encompass. A claim is indefinite where it merely recites a use without any active,

positive steps delimiting how this use is actually practiced.

Claim 5 is rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example *Ex parte Dunki*, 153 USPQ 678 (Bd.App. 1967) and *Clinical Products*, *Ltd.* v. *Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-5 are rejected under 35 U.S.C. 102(b) as being anticipated by Kakuda et al. (US Pat. No. 5, 501,866, collectively, "Kakuda").

Kakuda discloses a caffeine stimulation inhibitor and a method for inhibiting caffeine stimulation comprising theanine extracted from tea leaves and/or a substance having theanine as its main active ingredient, wherein the caffeine stimulation inhibitor is added to beverages and foods (see reference column 2, lines 38-46); abstract and claims. The composition is taught to be particularly useful for people who are hypersensitive to caffeine and/or desire to suppress the action of caffeine (including

Art Unit: 1615

those who desire to drink tea and coffee without impairing sleep) to allow them to consume caffeine-containing beverages or foods without worry over its effects (col. 2, lines 1-62). Kakuda discloses that the theanine may be crude or refined theanine and the theanine content in the caffeine stimulation inhibitor is preferably 10 to no more than 500 times the amount of caffeine ingested (col. 2, lines 47-51). The caffeine stimulation inhibitor is preferably used as an additive of beverages and foods and may also be absorbed in the form of tablets, capsules, granules or syrup (col. 2, lines 63-67). Kakuda discloses a method for inhibiting caffeine stimulation wherein the caffeine stimulation inhibitor is also in powder and liquid form (claims 2 and 4). At column 6, lines 25-29 (claim 11) Kakuda discloses a food or beverage product comprising beverages containing caffeine and theanine in an amount between 10 and 500 times greater than the amount of caffeine contained in said foods or beverages. Kakuda also discloses various experiments and studies demonstrating the antagonistic action of theanine (col. 3-5).

## Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Humera Sheikh whose telephone number is (703) 308-4429. The examiner can normally be reached on Monday through Friday from 7:00A.M. to 4:30P.M.

Application/Control Number: 09/980,620

Art Unit: 1615

Page 5

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page, can be reached on (703) 308-2927. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

THURMAN K. PAGE SUPERVISORY PATENT EXAMINER TECHNOLOGY SENTER 1600